Edwin Hardeman v. Monsanto Company
997 F.3d 941
9th Cir.2021Background
- Monsanto’s herbicide Roundup (active ingredient glyphosate) was registered by EPA; Edwin Hardeman used Roundup from the 1980s until 2012 and was diagnosed with non‑Hodgkin’s lymphoma (NHL) in 2015.
- Hardeman sued for failure to warn; case tried as the first federal MDL bellwether; jury found general and specific causation, awarded $5,267,634.10 compensatory and $75,000,000 punitive damages; district court reduced punitive to $20,000,000.
- Central legal questions: whether state-law failure-to-warn claims are preempted by FIFRA; admissibility of expert causation testimony under Daubert/Rule 702; admissibility of IARC and regulatory evidence; correctness of jury causation instruction and JMOL; constitutionality and amount of punitive damages.
- District court bifurcated trial (general causation; specific causation/liability/damages), admitted three general-causation experts and physicians who performed differential diagnosis for specific causation, admitted IARC’s “probably carcinogenic” classification (but excluded some other regulator materials as cumulative).
- Ninth Circuit affirmed: no FIFRA preemption (express or implied); district court applied Daubert correctly and did not abuse discretion admitting experts; evidentiary rulings harmless; jury instruction error harmless; punitive award reduced and reduced amount (3.8:1 ratio) upheld as constitutional though near the outer limit.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether FIFRA express preempts state failure-to-warn claims | Hardeman: state duty-to-warn enforces the same misbranding standard and is therefore consistent with FIFRA | Monsanto: EPA registration/label approval and EPA letter foreclose state-law warning requirements | Not preempted—state common-law warning claims are "equivalent to" and consistent with FIFRA (Bates test); EPA approvals are prima facie, not conclusive, and EPA letter lacked force of law |
| Whether FIFRA implied (impossibility) preempts state claims | Hardeman: manufacturer can change label under FIFRA procedures; no impossibility | Monsanto: EPA approval and regulatory process made it impossible to add a cancer warning | Not preempted—no clear evidence EPA would have forbidden a label change; FIFRA allows registrants to propose label changes and some minor changes via notification, so dual compliance possible |
| Admissibility of general‑causation expert testimony under Daubert/Rule 702 | Hardeman: experts relied on epidemiology, animal/cell studies, Bradford Hill factors and peer-reviewed meta-analyses | Monsanto: experts' reliance on certain epidemiology (case-control studies) and discounting of AHS made testimony unreliable | Affirmed—district court applied proper Daubert standard and did not abuse discretion in admitting general-causation experts; methodological disputes went to weight not admissibility |
| Admissibility of specific‑causation testimony (differential diagnosis) | Hardeman: physicians reliably ruled in glyphosate (based on general causation) and ruled out alternatives (HCV, idiopathy) | Monsanto: experts failed to reliably rule out idiopathy and HCV; relied on flawed studies or subjective judgment | Affirmed—district court did not abuse discretion; differential diagnosis was grounded in literature, records, and clinical experience and properly limited by court |
| Admissibility of IARC classification and regulatory evidence; jury instruction on causation | Hardeman: IARC classification necessary to avoid juror confusion from bifurcation; limiting instructions sufficient | Monsanto: IARC is prejudicial; admitting it while excluding other regulator conclusions was unfair; jury causation instruction misstated California law | Admitted IARC classification (but not report details) and certain regulator conclusions; exclusion of other regulators was not reversible error (or harmless); causation instruction error was inconsistent with CACI but harmless in context |
| JMOL on knowledge/knowability of glyphosate risk | Hardeman: scientific evidence made carcinogenic risk knowable by 2012 | Monsanto: science in 2012 did not establish knowable risk | JMOL denied—evidence allowed jury to find the link was knowable by 2012 |
| Punitive damages—availability and constitutional amount | Hardeman: punitive award appropriate to deter and punish Monsanto’s conscious disregard | Monsanto: insufficient reprehensibility; punitive award excessive and violates due process | Punitive damages permissible under California law; jury’s $75M was grossly excessive but district court’s remittitur to $20M (3.8:1 ratio) upheld as at the constitutional outer limit (single‑digit preferred; review fact‑specific) |
Key Cases Cited
- Bates v. Dow Agrosciences LLC, 544 U.S. 431 (2005) (FIFRA preemption test; state labeling claims survive when "equivalent to" federal misbranding standards)
- Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579 (1993) (gatekeeping standard for expert scientific testimony under Rule 702)
- Wyeth v. Levine, 555 U.S. 555 (2009) (agency pronouncements preempt state law only when they carry the force of law)
- PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011) (impossibility preemption requires that a party cannot independently comply with both federal and state law)
- Riegel v. Medtronic, Inc., 552 U.S. 312 (2008) (contrast where premarket approval carried preemptive effect under different statute)
- State Farm Mut. Auto. Ins. Co. v. Campbell, 538 U.S. 408 (2003) (constitutional guideposts for punitive damages: reprehensibility, ratio, comparable civil penalties)
- Wendell v. GlaxoSmithKline LLC, 858 F.3d 1227 (9th Cir. 2017) (Ninth Circuit guidance on differential diagnosis and expert latitude)
- Estate of Barabin v. AstenJohnson, Inc., 740 F.3d 457 (9th Cir. 2014) (standard of review for Daubert issues; gatekeeping obligations)